JonesResearch analyst Soumit Roy initiated coverage of Whitehawk Therapeutics (WHWK) with a Buy rating and $7 price target The company is positioned to achieve “potentially best-in-class designation” in the next-generation antibody-drug conjugates landscape, the analyst tells investors in a research note. The firm views Whitehawk as an “undervalued” pure play next-generation TOP1i ADC company that is targeting “validated but under crowded antigens.”
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WHWK:
- Whitehawk Therapeutics appoints Dugan as Chief Medical Officer
- Whitehawk Therapeutics Reports Q3 2025 Financial Results
- Cautious Optimism for Whitehawk Therapeutics: Balancing Innovation with Risk in Next-Gen ADCs
- Cautious Outlook on Whitehawk Therapeutics Amid Financial Challenges and Clinical Uncertainties
- Whitehawk Therapeutics reports Q3 EPS (26c) vs. (46c) last year